destiny-breast04: a ground-breaking trial in her2-low breast cancer
Published 2 years ago • 206 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
5:11
destiny-breast04: t-dxd provides significant improvement in os pfs in her2-low mbc
-
2:30
destiny-breast04: t-dxd in her2-low breast cancer regardless of molecular markers
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
0:44
biomarker-based personalization for her2-low breast cancer treatment in destiny-breast04
-
1:16
her2-low expression in breast cancer
-
2:05
latest news in her2-low breast cancer
-
5:02
reflections on the destiny-breast04 trial | patricia lorusso
-
4:18
asco 2022: destiny-breast04, paloma-2, reecur
-
1:09
the exciting new field of her2-low breast cancer
-
4:01
trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
0:56
remaining questions on the management of her2-low breast cancer
-
2:56
new breast cancer treatment option for patients with her2 breast cancer - connect with voa
-
1:32
destiny-breast15: t-dxd in patients with hr hr- and her2-low or her2 ihc 0 metastatic breast cancer
-
1:36
is her2-low a distinct subtype of breast cancer?
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm